Look back at pharma news in week to April 5

7 April 2019

By Barbara Obstoj-Cardwell. Editor

Merger and acquisition was in the news last week, with Novartis making its first M&A deal this year, buying IFM Tre along with its immunology pipeline for up to $1.575 billion. Also on the company front, a dispute has broken out between Amgen and Novartis regarding their migraine prevention drug Aimovig. Research news included ViiV Healthcare’s presentation of new data on its two-drug combination HIV drug Juluca. Meantime, with a Food and Drug Administration decision expected soon on Novartis’ gene therapy Zolgensma for spinal muscular atrophy (SMA), the latest ICER report on pricing for such drugs could be important.

Novartis bets $1.6 billion on a biotech’s anti-inflammatory drugs

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK